Novartis Ag

University of Pennsylvania

Leon Murphy

David Jonathan Glass

Joan Mannick

Jennifer Brogdon

Michael C Milone

Qilong Wu

Yongqiang Wang

Marco Ruella

Carl H June

Andreas Loew

Saar Gill

Hilmar Erhard Ebersbach

Jiquan Zhang

Saad Kenderian

David L Porter

Reshma Singh

Celeste Richardson

Huijuan Song

William Raj Sellers

Eugene Choi

Heather Huet

Gabriela Plesa

Brian Edward Vash

Boris Engels

Jan Weiler

Brian Walter Granda

Li Zhou

Lai Wei

Julia Jascur

Qiumei Yang

John Hastewell

Marcela V Maus

Thomas Huber

Abhishek Garg

John C Byrd

Carlos Garcia-Echeverria

Mariusz Wasik

Natarajan Muthusamy

Avery D Posey

Christine Fritsch

Amy Jo Johnson

Jan J Melenhorst

Felipe Bedoya

Jason A Dubovsky

Hans Bitter

Elena Orlando

Sauveur-Michel Maira

Paul Leslie Nicklin

Peter Finan

Corin Dorfmeier

Jihyun Lee

Jvan Galimberti

Saskia Maria Brachmann

Joseph Fraietta

Nicholas Wilcox

Ivan Galimberti

Abhishnek Garg

David Glass

Hilmar Ebersbach

The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.

Treatment of cancer using humanized anti-BCMA chimeric antigen receptor

The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.

Treatment of cancer using a CD123 chimeric antigen receptor

Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.

Regulatable chimeric antigen receptor

The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to nucleic acids comprising a truncated PGK promoter operably linked to a chimeric antigen receptor (CAR) specific to a tumor antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a tumor antigen as described herein.

Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor

Anti-BCMA chimeric antigen receptor

Cancer biomarkers and methods of using them are disclosed.

Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof

The present invention relates to a combination comprising (a) RAD001, or a pharmaceutically acceptable salt thereof, and (b) BEZ235, or pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential use for enhancement of an immune response; a pharmaceutical composition comprising such combination; a method of enhancing immune response in a subject comprising administration of said combination to a subject in need thereof; use of such combination for preparation of a medicament for the enhancement of an immune response; and a commercial package thereto.

Pharmaceutical combination of everolimus with dactolisib

The invention provides compositions and methods for treating diseases associated with expression of CLL-1. The invention also relates to chimeric antigen receptor (CAR) specific to CLL-1, vectors encoding the same, and recombinant cells comprising the CLL-1 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CLL-1 binding domain.

Treatment of cancer using a CLL-1 chimeric antigen receptor

The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.

Treatment of cancer using anti-CD19 Chimeric Antigen Receptor

The present invention relates, in part, to compositions and methods for enhancement of an immune response by partial mTOR inhibition, e.g., with low, immune enhancing, doses of an mTOR inhibitor, such as RAD001.

Low, immune enhancing, dose MTOR inhibitors and uses thereof

Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor

The present invention relates, in part, to compositions and methods for enhancement of an immune response by partial mTOR inhibition, for example, with low, immune enhancing, doses of an mTOR inhibitor, such as RAD001.

Low, immune enhancing, dose mtor inhibitors and uses thereof

Growing community of inventors

Cambridge, MA, United States of America

Leon Murphy